Mucosal and Serum Antibodies 3 Weeks after Symptomatic BA.2.86 Infection | New England
Journal of Medicine Skip to main content The New England Journal of Medicine homepage …

Background SARS-CoV-2 variants continue to circulate globally, even within highly
vaccinated populations. The first-generation SARS-CoV-2 vaccines elicit neutralizing …

Infection with SARS-CoV-2 in humans has caused a pandemic of unprecedented
dimensions. SARS-CoV-2 is primarily transmitted through respiratory droplets and targets …

Despite prolonged surveillance and interventions, the severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) and influenza viruses continue to pose a severe global health …

Introduction Several novel vaccine platforms aim at mucosal immunity in the respiratory tract
to block SARS-CoV-2 transmission. Standardized methods for mucosal sample collection …

Long-term humoral immunity is mediated by short-lived plasma cells (replenished by
memory B cells) and long-lived plasma cells. Their relative contributions are uncertain for …

BACKGROUND. There is uncertainty around the timing of booster vaccination against
COVID-19 in highly vaccinated populations during the present endemic phase of COVID-19 …

Waning immunity and continued virus evolution have limited the durability of protection from
symptomatic infection mediated by intramuscularly (IM)-delivered mRNA vaccines against …

Introduction Booster vaccinations are required to maintain protection against COVID-19.
COPD patients are at higher risk of developing severe illness following SARS-CoV-2 …

ABSTRACT SARS-CoV-2 persists in certain populations, even with vaccination and
boosters. Emerging evidence suggests that reductions in virus transmission and infection …